Consistent with the requirement of both GSDMD and GSDME for the release of IL-1β by NLRP3 and NLRP1 inflammasomes,525 the concurrent inhibition of these two proteins is essential to optimize therapeutic efficacy in the treatment of colitis.485 When investigating GSDMD inhibitors, it is crucial to account for the possibility of other GSDMs acting as reservoirs of GSDMD activity; (iii) The current investigation of GSDMD inhibitors is overwhelmingly centered on a single pyroptosis pathway involving caspases and GSDMD, which, admittedly, represents the most straightforward and efficient strategy. Here, NLRP3 is linked to colitis.